The Supreme Court has strongly criticised the Centre and pharmaceutical manufacturers over the significant disparity between the Maximum Retail Price (MRP) of medicines and their price to retailers, questioning the justification for such high margins and the perceived ineffectiveness of the National Pharmaceutical Pricing Authority (NPPA). The court reserved its verdict on petitions seeking strict price control and prevention of unethical overpricing of essential medicines.
India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies.
The GST Council has approved a proposal allowing pharmaceutical companies to claim Input Tax Credit (ITC) on free samples and goods destroyed or written off due to expiry, effective from the next fiscal year. This move aims to support manufacturing, liquidity, and exports within the sector.
Indian benchmark indices Sensex and Nifty opened the special Muhurat trading session on a bullish note, marking the beginning of the Hindu calendar Samvat 2083, driven by buying in key blue-chip stocks.
Indian benchmark indices Sensex and Nifty extended their rally in early trade, driven by strong buying in IT firms and an earnings-driven surge in Tata Group's retail arm, Trent, which reported a 25 per cent increase in net profit.
Indian benchmark equity indices, Sensex and Nifty, rallied in early trade, driven by sustained foreign fund inflows and a decline in crude oil prices. Foreign Institutional Investors (FIIs) have shown aggressive buying, investing a significant amount in Indian equities, while positive Q2 earnings and lower Brent crude prices are further supporting the market's upward trend. Track Sensex, Nifty on November 12, 2026.
Indian equity benchmark indices Sensex and Nifty slumped in early trade, ending a three-day rally, as profit-taking combined with concerns over surging retail inflation, which breached the Reserve Bank of India's upper tolerance limit, leading to anticipation of a policy rate hike. Track Sensex, Nifty on November 13.
Infosys co-founder S Gopalakrishnan states that software engineers must now be retrained to review and certify AI-written code, as AI has automated coding. He emphasises that AI-generated code cannot be fully trusted and requires human oversight. Gopalakrishnan also highlights that IT services and outsourcing will continue, and AI presents significant opportunities for new products and services, particularly for India and startups.
India's drug price regulator, NPPA, has revised downward the maximum retail price of 543 anti-cancer medicines, effective November 9. This follows an announcement enforcing trade margin rationalisation on 137 non-scheduled anti-cancer drugs, leading to significant price drops for several key brands.
Indian benchmark indices, Sensex and Nifty, closed largely unchanged after a volatile trading session, influenced by persistently high crude oil prices, selling pressure in major bank stocks, and investor caution ahead of the US Federal Reserve's policy decision.
Telangana IT Minister D Sridhar Babu stated that Gen Z will be the driving force behind the next wave of AI and green innovation. He urged young innovators to use their skills to solve real-world challenges, particularly in sustainability. The launch of the Green Skills and Applied AI Centre of Excellence in Hyderabad, a partnership between Telangana's IT Ministry, Microsoft, 1M1B, and MeitY Startup Hub, aims to equip graduates with industry-relevant skills in AI, green pharma, solar energy, EVs, and wind energy, with 100 job offers already announced.
Indian benchmark indices Sensex and Nifty ended marginally lower in the special Diwali Muhurat trading session, snapping a seven-day rally amid profit-taking by investors. Despite a positive start, the Sensex dipped 28.62 points to 80,999.40, and the Nifty declined 43.95 points to 24,986.40.
Indian stock markets are set to be influenced this week by a confluence of factors including quarterly corporate earnings, the US Federal Reserve's interest rate decision, fluctuations in crude oil prices, and ongoing geopolitical developments in West Asia.
Indian equity markets, represented by the Sensex and Nifty 50, concluded Samvat 2082 with significant weekly gains, marking their strongest performance in nearly six years, despite it being their weakest Samvat in 15 years overall. The late recovery was driven by hopes of tax changes, resilient corporate earnings, and easing geopolitical tensions.
Indian benchmark indices Sensex and Nifty extended their winning streak in early trade, with Sensex jumping 614.66 points and Nifty rallying 149.80 points. This surge is attributed to a sharp correction in crude oil prices, continued foreign fund inflows, and positive Q2 results, creating an ideal environment for the market rally to continue.
Indian benchmark indices, Sensex and Nifty, saw significant gains in early trade, primarily driven by a strong performance from Reliance Industries following its record quarterly profit announcement and a notable decline in global crude oil prices. Positive foreign fund inflows and a buoyant trend in Asian markets further contributed to the market's optimism.Track Sensex, Nifty on November 2.
Indian benchmark indices, Sensex and Nifty, closed significantly higher, with the Sensex rallying 1,233 points and the Nifty climbing to 23,440.80. This surge was primarily fuelled by a sharp increase in Reliance Industries' share price following strong quarterly earnings and a notable decline in crude oil prices.
Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
PAPs can reduce expenditure by 30 to 60 per cent for some expensive immunotherapies and targeted therapies.
Indian benchmark equity indices, Sensex and Nifty, experienced a decline in early trade due to elevated crude oil prices, ongoing geopolitical uncertainties, and investor caution ahead of the US Federal Reserve's policy decision later this week. Track Sensex, Nifty on October 26.
Torrent Pharma has emerged as a top sectoral pick for brokerages, driven by healthy growth in India revenues and improved gross margins, leading to a 44 per cent stock return over the past year.
India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has significantly reduced the maximum retail prices (MRPs) of 543 cancer drug brands and pack sizes, with some reductions reaching up to 93 per cent. However, expensive innovator drugs from multinational corporations, including high-selling Bevacizumab and immunotherapy Keytruda, remain unaffected, highlighting limitations in the price control intervention.
Bristlecone, a Mahindra Group company, reported a 24% year-on-year topline growth and aims for a billion-dollar valuation. The AI-powered supply chain services provider is expanding its offerings to include data analytics, AI, and product engineering, focusing on making supply chains more resilient for its global clients across high-tech, retail, manufacturing, and life sciences segments.
Mahindra Group's Bristlecone, a supply chain services provider, has reported a 24 per cent year-on-year topline growth and aims for a billion-dollar valuation. The company is expanding its offerings in AI, data analytics, and product engineering, focusing on resilient supply chains for global enterprises.
Indian benchmark indices, Sensex and Nifty, recovered early losses on Wednesday, driven by strong buying in IT stocks and HDFC Bank, sustaining the previous session's recovery despite FII outflows. Track Sensex, Nifty on October 14.
Police in Bengaluru have arrested Balasubramanian, a partner in DM Pharma, in connection with an interstate counterfeit drug racket. This arrest follows the apprehension of alleged kingpin Prashanth Rajan Babu. The Special Investigation Team is probing the supply chain, financial transactions, and distribution channels of fake medicines worth nearly Rs 5 crore, which were being relabelled as premium brands.
The Supreme Court has strongly criticised the exorbitant markup on cancer drugs by hospitals, calling it "carnage" and "broad daylight dacoity." The court highlighted a case where a cancer drug was marked up ten times its retail price and urged the Centre to implement a uniform 16% margin on all medicines. It also raised concerns about hospitals forcing patients to buy medicines from their in-house chemists.
'I have seen in Agra parents selling their buffalo, which is their sole source of livelihood, to buy expensive medicines to treat their child.' 'I was very moved by such cases and therefore approached the court to regulate the price of medicines in our country.'
Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
More patients can now afford semaglutide, but the early excitement around the drug is fading.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Indian IT stocks have experienced their most significant weekly surge in 18 years, with the Nifty IT index climbing 11.72 per cent, as a global sell-off in AI-linked equities redirected investor attention towards India's IT services sector. This shift aligns with a JP Morgan report identifying India as a 'natural AI hedge' due to its large, liquid market and strong domestic institutional investor base.
Indian benchmark indices, Sensex and Nifty, closed lower on Tuesday, with the Sensex declining 329.91 points to 74,529.08 and the Nifty dipping 85.30 points to 23,329, primarily dragged by underperformance in IT, financial, and capital goods stocks despite positive global market trends and easing crude oil prices.
Pharma major Lupin is significantly increasing its focus on biosimilars, aiming for a turnover of nearly $500 million from this segment over the next five years, driven by new product launches and expanded presence in key global markets like the US, Europe, and Japan.
The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse in Pune. This action follows alleged violations related to packaging, storage, documentation, and recall of Reactin Plus Tablets, a Schedule H drug. The FDA cited issues like misbranding, inadequate storage conditions, and deficiencies in record-keeping, reiterating its commitment to ensuring medicine safety and compliance.
They had bought Rs 29,631 crore worth of shares in August.
Indian benchmark indices Sensex and Nifty rebounded in early trade after two days of losses, driven by easing crude oil prices and strong buying in blue-chip IT stocks, despite continued global uncertainties. Track Sensex, Nifty on September 30.
HSBC has emerged as the leading international bank in facilitating fundraising for Indian companies through bonds, syndicated loans, and IPOs during January-September 2026, according to Hitendra Dave, CEO of HSBC India.
Indian benchmark indices Sensex and Nifty saw a significant rebound in early trade, with the Sensex surging over 700 points, driven by a decline in crude oil prices, easing concerns over Federal Reserve tightening, and the appointment of Anup Bagchi as the new MD and CEO of HDFC Bank.